InnoCare licensing deal flops due to lack of upfront cash
The Chinese biotech agreed to sell some of the rights to its flagship drug for a sum that could exceed $2 billion but investors were unhappy with the fine print…
BRIEF: InnoCare, KeyMed in antibody licensing agree with Prolium
Biopharmaceutical company InnoCare Pharma Ltd. (9969.HK; 688428.SH) announcedon Monday that it, along with KeyMed (2162.HK) and their joint venture have signed a licensing deal for one of their products with…
FAST NEWS: InnoCare inches closer to profitability on strong sales gains
The latest: InnoCare Pharma Ltd. (9969.HK) announced Tuesday its first-quarter revenue jumped 59% year-over-year to 189 million yuan ($27.3 million), while its net loss narrowed 90% to 12.41 million yuan. Looking…
Henlius Swallows Bitter Pill in Watered-Down Licensing Deal
The innovative drug company will receive less benefits from an existing licensing deal after revisions to reflect high R&D costs Key Takeaways: Henlius Biotech will receive up to $11 million…
FAST NEWS: InnoCare Pharma’s Loss Soars on R&D Costs, Exchange Losses
The latest: InnoCare Pharma Ltd. (9969.HK) said it expects to report its net loss soared about 13 times to 910 million yuan ($134 million) last year, according to a profit…
Losses Mount at InnoCare but Cash Cushion Dulls the Pain
The cancer drug developer logged another loss in the latest quarter but a cash pile of more than 9.2 billion yuan can sustain its business for the next five yearsKey…
No Early Relief for JW Therapeutics from Cancer Wonder Drug
The biotech company logs revenue of 66 million yuan from its cutting-edge cancer therapy, but losses jump more than 50% to nearly 430 million yuan. Key Takeaways: JW Therapeutics prices…
Recent Articles
InnoCare licensing deal flops due to lack of upfront cash
9969.HK
688428.SHG
BRIEF: InnoCare, KeyMed in antibody licensing agree with Prolium
9969.HK
688428.SHG
RELATED ARTICLES
-
Precision cancer drugs show promise for Kelun-Biotech
6990.HK -
RemeGen’s $4.2 billion licensing deal falls flat with investors
9995.HK 688331.SHG
-
3SBio hits the big time with $6 billion cancer drug deal
1530.HK
-
HBM notches up another mega deal but is the model sustainable?
2142.HK
-
XtalPi scores landmark deal for AI drug discovery
2228.HK
-
CSPC Pharma teases big bucks deals after earnings miss
1093.HK
-
Alphamab stake sale could signal harder times ahead
9966.HK
